x min read

Stocks in Aggressive Mood: Chicago Bridge & Iron Company N.V. (NYSE:CBI), ArQule Inc. (NASDAQ:ARQL), Gilead Sciences Inc. (NASDAQ:GILD)

Stocks in Aggressive Mood: Chicago Bridge & Iron Company N.V. (NYSE:CBI), ArQule Inc. (NASDAQ:ARQL), Gilead Sciences Inc. (NASDAQ:GILD)
Written by
Ryan Mitchell
Published on
November 12, 2014
Copy URL
Share on LinkedIn
Share on Reddit
Share on Twitter/X
Share on Facebook
InsidrFinancial

Chicago Bridge & Iron Company N.V. (NYSE:CBI) Trend Analysis reported that it has awarded a contract worth in excess of $40M by Coffeyville Resources Refining & Marketing; also was awarded for 760 Megawatt combined-cycle gas turbine power station. The firm also reported that it has been awarded a contract by Calpine Mid-Merit, LLC, an affiliate of Calpine Corp., for the initial development phase of a combined-cycle gas turbine power station in Peach Bottom Township, Pennsylvania. The 760 megawatt unit will be built adjacent to the existing York Energy Center. Chicago Bridge & Iron Company N.V. (NYSE:CBI) stock price closed at $55.04 with the total traded volume of 2.52 Million shares. Its price to sales ratio ended at 0.47. Its market capitalization is 5.960 Billion. The stock owned by the Financial Institutions was 80.80% while by insiders was 0.80%.ArQule Inc. (NASDAQ:ARQL) Trend Analysis released an contract with the National Human Genome Research Institute of the National Institutes of Health providing for the clinical development of ARQ 092 in Proteus syndrome. ArQule Inc. (NASDAQ:ARQL) begun last trade with a price of $1.15 and throughout the trading session climbed at a high of $1.22. The day-trade ended with -1.71% to $1.15. The stock is going forward to its 52 week low with 10.58% and lagging behind from its 52 week high price with -60.62%. ARQL last month stock price volatility remained 5.76%.Gilead Sciences Inc. (NASDAQ:GILD) Trend Analysis released data from three Phase 2 open-label studies evaluating the safety and efficacy of Sovaldi. The first study, GS-US-342-0109 (Oral #197), assessed 12 weeks of SOF plus GS-5816 with and without RBV in treatment-experienced genotype 1 and 3 patients with and without cirrhosis. The genotype 1 patients had all failed a prior treatment course that included a protease inhibitor. Gilead Sciences Inc. (NASDAQ:GILD) has the market capitalization of 163.5 Billion. Shares of firm surged 0.93% to close at $108.01 with the total traded volume of 12.19 Million. The firm has current ratio of 2.10 for the most recent quarter.

Discover Hidden Gems

Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.

Recommended for You